Luyan Pharmaceuticals: The company's operations are normal with no significant undisclosed matters that should be disclosed.

Lu Yan Pharmaceutical announced that the closing price of the company's stock has deviated by more than 20% for three consecutive trading days, indicating abnormal fluctuations in the stock trading. After verification, the information disclosed by the company in the previous period does not require correction or supplementation, the recent operation is normal, both internal and external operating conditions have not undergone major changes, and no significant undisclosed information that may or has had a significant impact on the company's stock trading price has been found in public media reports. The company, controlling shareholder, and actual controller do not have any significant undisclosed matters that should be disclosed, or major matters in the planning stage. During the period of abnormal stock fluctuations, the controlling shareholder and actual controller do not engage in trading the company's stock.